The aim – to evaluate the safety and efficacy of quercetin in addition to standard therapy in reperfused patients with acute coronary syndrome with ST-segment elevation (STEMI) as compared to standard therapy alone.
Material and methods. PROTECT study is a multicenter, open-label, randomized, comparative, controlled, parallel-group study. Patients with anterior wall STEMI hospitalized during the first 6 hours after symptoms onset are included. Mechanical or pharmacological reperfusion is required for all patients. The inclusion started in April 2014. As of March 2016, 90 patients were randomized at 12 centers in Ukraine. It is expected that the recruitment will be completed in 2017. To confirm cardioprotective properties of the study drug we selected enzymatic infarct size measurement. Infarct size will be analyzed based on serial CKMB assessment with futher calculation of the area under time-concentration curve. Blood samples are collected at baseline and then at stated intervals during 66 hours after inclusion. To assess the extent of myocardial injury and its changes over time surface ECG evaluation before and after revascularization procedures will be performed.
Conclusion. Reperfusion injury contributes to up to 50 % of the total myocardial damage. Studies exploring the potential of new therapeutic options to limit reperfusion injury are actual and are eagerly awaited.